Randomized controlled trial comparing mini-sling with transobturator sling for the treatment of stress urinary incontinence.

INTRODUCTION AND HYPOTHESIS: Stress urinary incontinence (SUI) is the involuntary loss of urine on effort and is a condition that negatively interferes with various aspects of a woman's life. This study aimed to demonstrate the non-inferiority of the less invasive single-incision mini-sling (SIMS) method in objective and subjective cures in relation to tension-free transobturator tape (TOT) in two analyses, per protocol and intention to treat, and secondarily to evaluate complications and quality of life. METHODS: This study was a randomized controlled trial (RCT). Participants in this study included 105 women with a clinical diagnosis of stress predominant urinary incontinence and urodynamic results demonstrating SUI and absence of detrusor overactivity. Patients were evaluated pre- and postoperatively through anamnesis, physical examination, urinalysis, urine culture and susceptibility testing, simplified pad test, the Urinary Incontinence-Specific Quality of Life Instrument (I-QOL) and Urogenital Distress Inventory Short Form (UDI-6). RESULTS: Regarding the objective cure, SIMS was non-inferior to TOT (p < 0.05). However, the same was not found for the subjective cure (p > 0.05). There were no differences in the complication rates (p > 0.05). However, in the TOT group, bladder perforation (2.4%), tape exposure (2.4%) and urinary retention occurred, lasting > 7 days (2.4%). In both groups, there was improvement in quality of life after surgery, without significant differences (p > 0.05). CONCLUSIONS: The non-inferiority of SIMS in relation to TOT was only demonstrated in the objective cure. There were no significant differences between groups regarding complications and quality of life.

Prospective and randomized clinical trial comparing transobturator versus retropubic sling in terms of efficacy and safety.

INTRODUCTION AND HYPOTHESIS: The midurethral sling is the most commonly performed surgical procedure for stress urinary incontinence (SUI). We compared the efficacy of transobturator tape (TOT) and retropubic (RP) slings by evaluating objective and subjective cure rates at 12 months postsurgery and evaluate the impact on quality of life (QoL) and record intra- and postoperative complications. METHODS: This was a randomized, controlled, prospective, clinical trial with analysis of noninferiority. The hypothesis was that the TOT sling is not inferior to the RP sling. A total of 92 women with SUI were selected and randomized into two groups: TOT and RP slings. RESULTS: Eighty-one patients maintained follow-up 12 months postoperatively. In the per-protocol analysis, the objective cure rates were 100% for the RP sling and 93% for the TOT sling (p = 0.029). The subjective cure rates were 92% for the RP sling and 90% for the TOT sling (p = 0.02). Because none of the upper limits of the confidence interval (CI) were above the noninferiority margin, noninferiority of the TOT sling could be concluded. In contrast, the intention-to-treat analysis could not show that the TOT sling was not inferior to the RP sling, because the upper limit of the CI surpassed the noninferiority margin. Postoperative complications were similar for both groups, except for higher urinary retention rates in the RP group. Regarding QoL, there was a significant improvement. CONCLUSIONS: The cure rates of the per-protocol analysis showed the noninferiority of the TOT relative to the RP sling. The RP sling group exhibited higher urinary retention. Quality of life improved significantly in both groups.

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.

BACKGROUND: We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis. METHODS: Healthy postmenopausal osteoporotic women (N = 7,492; mean age, 66.4 years) were randomized to daily doses of bazedoxifene 20 or 40 mg, raloxifene 60 mg, or placebo for 3 years. Safety and tolerability were assessed by adverse event (AE) reporting and routine physical, gynecologic, and breast examination. RESULTS: Overall, the incidence of AEs, serious AEs, and discontinuations due to AEs in the bazedoxifene groups was not different from that seen in the placebo group. The incidence of hot flushes and leg cramps was higher with bazedoxifene or raloxifene compared with placebo. The rates of cardiac disorders and cerebrovascular events were low and evenly distributed among groups. Venous thromboembolic events, primarily deep vein thromboses, were more frequently reported in the active treatment groups compared with the placebo group; rates were similar with bazedoxifene and raloxifene. Bazedoxifene showed a neutral effect on the breast and an excellent endometrial safety profile. The incidence of fibrocystic breast disease was lower with bazedoxifene 20 and 40 mg versus raloxifene or placebo. Reductions in total and low-density lipoprotein levels and increases in high-density lipoprotein levels were seen with bazedoxifene versus placebo; similar results were seen with raloxifene. Triglyceride levels were similar among groups. CONCLUSION: Bazedoxifene showed a favorable safety and tolerability profile in women with postmenopausal osteoporosis. TRIAL REGISTRATION NUMBER: NCT00205777; Trial registration date: September 16, 2005.

Effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal osteoporosis patients.

This multicenter, open-label study evaluated the effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal women with osteoporosis in Brazil. Entry requirements included: osteoporosis of the spine/femoral neck diagnosed by a bone mineral density (BMD) T-scoreor=1 dose of study drug (intent-to-treat [ITT] population), and 390 completed treatment (81%). After 12 wk, CTX decreased in 94% of patients (from 0.419+/-0.234 to 0.158+/-0.171 microg/L, p<0.0001). Mean CTX reduction was 60.6%. Patient satisfaction was good/excellent in 91.7% of patients. A total of 156 adverse events (AEs) were reported by 113 (23.5%) patients in the ITT population. Digestive symptoms emerged or worsened in 7.1% and 3.5%, respectively. Five patients (1.0%) experienced serious AEs, not considered to be related to risedronate. In conclusion, risedronate significantly reduced serum CTX after 12-wk treatment. Almost all patients reported good/excellent satisfaction.

Study of the polymorphism rs3025058 of the MMP-3 gene and risk of pelvic organ prolapse in Brazilian women.

OBJECTIVE: To analyze the polymorphism -1171 5A / 6A rs3025058 of the MMP-3 gene and the risk for pelvic organ prolapse (POP). STUDY DESIGN: This is a cohort study. All patients attended the Urogynecology and Vaginal Surgery Section of the FMABC, from 2014 to 2016 and they were randomly recruited by the researchers at the first medical appointment. We selected 112 patients with symptomatic POPs and 180 patients with normal pelvic floors. The single nucleotide polymorphism (SNP) 5A / 6A of MMP-3 was determined by polymerase chain reaction (PCR) and analysis of the restriction fragments in both groups. Chi-squared test was used to compare the frequencies of polymorphisms between the groups. For those characteristics with statistical relevance, the crude odds ratio (OR) and its respective 95% confidence intervals were calculated; and, by logistic regression, were adjusted for each of the other characteristics, obtaining the adjusted OR. Hardy-Weinberg gene balance was determined using Pearson's Chi-squared test. Values of p < 0.05 were considered statistically significant. RESULTS: Logistic regression of factors associated with genital prolapse showed that age (adjusted OR = 11.89, 95% CI, 3.53-40) and home delivery (adjusted OR = 9.645, 95% CI, 3.35-27.7) remained risk factors for genital prolapse in the sample studied. There was no statistically significant difference between the groups in the distribution of genotypes, even after calculating the contribution of the 5A recessive allele in the aggregated genotypes (5A / 5A + 5A / 6A). CONCLUSION: The polymorphism -1171 5A / 6A rs3025058 of the MMP-3 gene was not associated with the risk for POP. Age and home delivery were significantly associated with increased risk for the disease.

Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow.

OBJECTIVES: To evaluate the lipid profile, insulin resistance and vasomotricity, and the interaction between these factors, in postmenopausal women receiving hormone therapy. METHODS: A prospective, randomized, double-blind study was carried out in which 77 postmenopausal women received one of the three treatment regimens: (A) 2mg oral micronized estradiol (E2) (n=25); (B) 2mg oral E2+1mg oral norethisterone acetate (NETA) (n=28); or C) placebo (n=24), daily for 6 months. Evaluations were carried out at baseline and at the end of treatment on lipid and lipoprotein profiles, homeostasis model assessment of insulin resistance (HOMA-IR) and pulsatility index (PI) of the internal carotid artery by Doppler ultrasonography. RESULTS: Mean increases of 15.6% and 2.4% and a reduction of 6.4% in high-density lipoprotein (HDL) levels were found for the E2, E2+NETA and placebo groups, respectively. Reductions of 9.5% and 3.7% and an increase of 12.1% in low-density lipoprotein (LDL), and reductions of 20.0% and 3.8% and an increase of 28.8% in the LDL:HDL ratio were found for the E2, E2+NETA and placebo groups, respectively (p<0.001 in all cases). Insulin levels and HOMA-IR decreased 12.8% and 12.3% in the E2 group and increased 12.9% and 16.0% in the E2+NETA group (p<0.05), respectively. Carotid PI following treatment was 1.18+/-0.23, 1.38+/-0.20 and 1.41+/-0.21 for the E2, E2+NETA and placebo groups, respectively (p=0.0006). CONCLUSIONS: Oral estrogen therapy led to an improvement in lipid profile, insulin resistance and carotid blood flow, which was cancelled when NETA was associated.

Effect of raloxifene on the vaginal epithelium of postmenopausal women.

OBJECTIVE: The objective was to analyze the effect of raloxifene on the vaginal epithelium of postmenopausal women. STUDY DESIGN: In this non-randomized clinical trial, 80 women (mean age = 60.6 years) were prospectively studied. Forty patients received 60 mg/day of raloxifene (RG), and 40 women constituted a non-treated control group (CG), paired by age and time since menopause. The treated group consisted of patients with osteoporosis of the lumbar spine. Those with a diagnosis of infection in the lower genital tract and using hormone therapy (HT) up to 6 months prior to the study were excluded. Vaginal smears were collected at baseline and after 6 months of intervention. The vaginal maturation value (VMV) was determined, and counts of superficial, intermediate and parabasal cells were performed. Smears were analyzed by only one cytopathologist who was blinded to patient data. The t-test, Wilcoxon test, and Chi-Squared test were used in the statistical analysis. RESULTS: The study groups were homogeneous regarding age, time since menopause, parity, HT use, smoking, and body mass index. No statistically significant differences were observed in VMV median values (RG, 39.7 and 35.7; CG, 50.0 and 50.0, respectively) or in the percentage of superficial, intermediate and parabasal cells between the groups at baseline and after 6 months (p>0.05). There was no significant correlation between VMV and age, time since menopause, previous HT use, or body mass index, in either of the groups. CONCLUSION: Treatment with raloxifene for 6 months has no effect on the maturation of the vaginal epithelium in postmenopausal women with osteoporosis.

Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.

OBJECTIVE: The aim of the study was to evaluate efficacy of fractional CO2 vaginal laser treatment (Laser, L) and compare it to local estrogen therapy (Estriol, E) and the combination of both treatments (Laser + Estriol, LE) in the treatment of vulvovaginal atrophy (VVA). METHODS: A total of 45 postmenopausal women meeting inclusion criteria were randomized in L, E, or LE groups. Assessments at baseline, 8 and 20 weeks, were conducted using Vaginal Health Index (VHI), Visual Analog Scale for VVA symptoms (dyspareunia, dryness, and burning), Female Sexual Function Index, and maturation value (MV) of Meisels. RESULTS: Forty-five women were included and 3 women were lost to follow-up. VHI average score was significantly higher at weeks 8 and 20 in all study arms. At week 20, the LE arm also showed incremental improvement of VHI score (P = 0.01). L and LE groups showed a significant improvement of dyspareunia, burning, and dryness, and the E arm only of dryness (P < 0.001). LE group presented significant improvement of total Female Sex Function Index (FSFI) score (P = 0.02) and individual domains of pain, desire, and lubrication. In contrast, the L group showed significant worsening of pain domain in FSFI (P = 0.04), but FSFI total scores were comparable in all treatment arms at week 20. CONCLUSIONS: CO2 vaginal laser alone or in combination with topical estriol is a good treatment option for VVA symptoms. Sexual-related pain with vaginal laser treatment might be of concern.

Effects of soy protein and resistance exercise on body composition and blood lipids in postmenopausal women.

OBJECTIVE: To assess the effect of soy protein and progressive resistance training on body composition and lipids in postmenopausal women. DESIGN: In a controlled trial, 46 postmenopausal women were randomized to one of four groups: 25 g of soy protein (SP, n=10), 25 g of soy protein plus resistance exercise (SPE, n=14), 25 g of maltodextrine (placebo) (PL, n=11), or placebo plus resistance exercise (PLE, n=11). Progressive resistance training was held three times a week for 16 weeks and included 8 exercises (3 series of 8-12 repetitions). At baseline and after 16 weeks, body mass index, waist circumference (WC), body fat, muscle mass and serum lipid levels were measured. To confirm isoflavone absorption, urinary concentrations were determined. The t-test of Student and ANOVA were used in the statistical analysis. RESULTS: Subjects were classified as overweight and showed android fat distribution. Urinary isoflavone excretion indicated compliance to soy protein treatment. After 16 weeks of intervention, both SPE and PLE groups showed a significant increase of 1.3 kg in muscle mass and reduction in WC of -1.4 and -2.1cm, respectively (p<0.05). Significant decreases in the mean values of total cholesterol and LDL (-29.0 and -24.0 mg/dL, p<0.001 and p<0.006, respectively) were observed in the users of soy protein alone (SP). CONCLUSIONS: Soy protein supplementation did not influence the indicators of body composition. However, it exerted possible favorable effects on lipid profile in postmenopausal women. The increase in muscle mass and reduction in abdominal fat were correlated with resistance training.

Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels.

BACKGROUND: This study was conducted to compare the effects of two contraceptive pills with different doses of the same components, on plasma androgen levels and female sexual function among women without previous sexual dysfunction. STUDY DESIGN: The participants were randomized into two groups, to receive pills containing ethynylestradiol (EE) 30 mcg and levonorgestrel (LNG) 150 mcg or EE 20 mcg and LNG 100 mcg, for six cycles. Sexual function was assessed using a standardized questionnaire [Female Sexual Function Index (FSFI)]. Hormone assays were performed at baseline and after the sixth cycle. RESULTS: Forty-nine women were included in the EE30/LNG150 group and 48 in the EE20/LNG100 group. EE30/LNG150 group presented 54% and 67% decreases of total testosterone and free androgen index, respectively, with statistical significance. EE20/LNG100 presented reductions of 20% and 42%, respectively, but without statistical significance. Both groups showed improvements in the FSFI "desire" score, but with statistical significance only for EE20/LNG100 group. CONCLUSIONS: EE30/LNG150 decreased plasma androgen levels, but there was no impairment in sexual desire, on the other hand, sexual desire score increased with EE20/LNG100 formulation.

A variable-temperature diffuse reflectance infrared fourier transform spectroscopy study of the binding of water and pyridine to the surface of acid-activated metakaolin.

Four metakaolins were prepared by heating a Spanish kaolin at 600, 700, 800, and 900 degrees C for 10 h. Following preliminary optimization, these metakaolins were acid activated in 6 M hydrochloric acid at 90 degrees C for 6 h; the samples calcined at 600, 700, and 800 degrees C produced the highest surface area solids and were selected for further study. Variable-temperature diffuse reflectance infrared Fourier transform spectroscopy analysis of the resulting acid-activated metakaolins (AAMKs) identified a wide range of hydrogen bond strengths in adsorbed water at room temperature. Above 300 degrees C it was possible to fit the broad hydroxyl stretching band to seven contributing components at 3730, 3700, 3655, 3615, 3583, 3424, and 3325 cm(-1). As the sample temperature was increased, the 3730 cm(-1) band increased in intensity as the water hydrogen bonded to AlOHAl was thermally desorbed. The other six bands decreased in intensity. The spectra of adsorbed pyridine indicated the presence of both Brönsted and Lewis acid sites on the surface of the air-dried AAMKs. Preheating the AAMK at 200 degrees C prior to pyridine sorption reduced the number of Brönsted acid sites and increased the number of thermally stable Lewis acid sites. A reduction in the amount of adsorbed pyridine after pretreating the AAMK at 400 degrees C was tentatively attributed to a reduction in surface area. This was reflected in fewer thermally stable Lewis acid sites in the AAMK pretreated at 400 degrees C compared to the number present in the sample pretreated at 200 degrees C.

Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women.

OBJECTIVE: The objectives were to evaluate mammographic changes in breast density that are associated with raloxifene or hormone therapy and to compare the safety profiles of the two therapies. STUDY DESIGN: Postmenopausal women older than 60 years who had a bone mineral density T-score of < or =-1 were assigned randomly to receive raloxifene hydrochloride 60 mg/day or continuous-combined hormone therapy that consisted of conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day in a 1-year, open-label study. Radiologists who were blinded to the treatment assignment assessed the mammograms according to the American College of Radiology Breast Image Reporting and Data System breast density categories. Breast density changes were analyzed for treatment differences. RESULTS: After 12 months of treatment, 0.9% of the women who received raloxifene had increased mammographic breast density compared with 27.4% of the women who received continuous-combined hormone therapy (P <.001). In the continuous-combined hormone therapy group, 77% of the women reported breast tenderness at any time during the study, compared to 22% of the women in the raloxifene group. CONCLUSION: In postmenopausal women with low bone mass, raloxifene therapy for 12 months does not increase mammographic breast density, whereas continuous-combined hormone therapy substantially increases breast density in a significant number of women.

Estudo de mecanismos e fatores relacionados com o abuso sexual em crianças e adolescentes do sexo feminino / Study of mechanisms and factors related to sexual abuse in female children and dolescents

Objetivo:estudar mecanismos e fatores relacionados com o abuso sexual, comparando suas freqüências entre vítimas crianças e adolescentes. Métodos: estudo retrospectivo de 617 vítimas de abuso sexual atendidas entre julho de 1994 e agosto de 1999 pelo Centro de Referência da Saúde da Mulher: 71 crianças (idade<10 anos) e 546 adolescentes (10 a 20 anos). As variáveis de estudo foram crime sexual; constrangimento; presunção de violência; tipificação do agressor; número de agressores; situação da vítima no momento do crime; e ocorrência de traumas físicos. Os dados foram informatizados em programa Epi Info 6 e os resultados analisados pelo teste de X2. Resultados: o estupro ocorreu em 90,8 por cento das adolescentes e o atentado violento ao pudor em 46,5 por cento das crianças. A violência presumida (VP) foi mais freqüente nas crianças (63,4 por cento) e a grave ameaça nas adolescentes (63,2 por cento). A inocencia consilli foi VP exclusivas entre crianças, atingindo 59,5 por cento das dolescentes. Entre crianças, 84,5 por cento foram abusadas por agressores identificáveis, geralmente do núcleo familiar, enquanto desconhecidos violentaram 72,3 por cento das adolescentes. Nas crianças, o abuso ocorreu em 42,3 por cento em suas residências e em 28,2 por cento na do agressor. Adolescentes foram vitimadas durante atividades cotidianas (34,8 por cento) e no percurso do trabalho ou escola (28,4 por cento). A maioria das pacientes não apresentou traumas físicos genitais ou extragenitais. Conclusões: crianças foram submetidas, principalmente, ao atentado violento ao pudor, perpetrado por agressor conhecido, por meio de violência presumida e em ambientes privados. Nas adolescentes predominou o estupro por agressores desconhecidos, sob grave ameaça, em ambientes não domésticos

Incidência de eventos adversos e seu impacto sobre a descontinuidade do tratamento entre mulheres tratadas com raloxifeno ou terapia da reposição hormonal / Impact of adverse events on discontinuation among postmenopausal women treated with raloxifene or estrogen-progestin

Avaliar os perfis de eventos adversos do tratamento com raloxifeno e com reposição hormonal e seu impacto sobre a descontinuidade entre mulheres na pós-menopausa com 60 anos ou mais. Mulheres na pós-menopausa com osteopenia ou osteoporose vivendo na América Latina foram randomizadas para tratamento com raloxifeno 60 mg/dia (RLX, n=140) ou terapia hormonal combinada contínua (TRH, n=140) neste estudo aberto, de um ano. A freqüência e o tempo até a descontinuidade de todos os eventos adversos (EA)espontâneos e dos nove eventos adversos solicitados (sangramento uterino, ondas de calor, sensibilidade mamária, suores noturnos, sensação de inchaço, desconforto pélvico, transtornos do humor, cãibra nas pernas, e secura vaginal) foram determinados para ambos os grupos. Um Questionário de Qualidade de Vida Específico para Menopausa (Menopause-Specific Quality of Life Questionnaire(MENQOL) também foi completado. Sensibilidade mamária e sangramento vaginal foram os EAs mais freqüentes entre as usuárias de TRH, enquanto ondas de calor foram mais freqüentes entre as pacientes tratadas com RLX (p<0,001). Não houve diferenças entre os grupos em relação a outros EAs. As pacientes recebendo RLX apresentaram menor probabilidade de descontinuar o tratamento devido a um EA espontâneo ou solicitado (4 por cento vs. 18 por cento, p<0,001). Das pacientes recebendo RLX, 0,7 por cento descontinuaram o tratamento devido a um EA solicitado (cãibra nas pernas) e 3,6 por cento devido a um EA espontâneo. As pacientes recebendo TRH descontinuaram devido a sangramento vaginal (5,7 por cento), sensibilidade mamária (2,1 por cento), transtornos do humor (0,7 por cento) ou a um EA espontâneo (9,3 por cento). A probabilidade de descontinuidade por qualquer razão foi menor entre as pacientes recebendo RLX (RR=0,60; 95 por cento CI, 0,40-0,89). A maioria dos sub-escores do MENQOL melhoraram no final do tratamento em ambos os grupos. Mulheres na pós-menopausa com 60 anos ou mais, com baixa massa óssea e recebendo RLX apresentaram menor probabilidade de descontinuar o tratamento devido a um EA que as recebendo TRH. Conseqüentemente, o tratamento com RLX pode melhorar a aderência ao tratamento a longo-prazo.